BioLife Solutions Inc (NASDAQ:BLFS) VP Sells $53,910.00 in Stock

BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of BioLife Solutions stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $17.97, for a total transaction of $53,910.00. Following the sale, the vice president now directly owns 44,074 shares in the company, valued at approximately $792,009.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Todd Berard also recently made the following trade(s):

  • On Monday, July 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.58, for a total transaction of $49,740.00.
  • On Monday, June 17th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.47, for a total transaction of $52,410.00.

NASDAQ BLFS opened at $20.78 on Thursday. The firm’s 50-day moving average is $17.95 and its two-hundred day moving average is $17.59. BioLife Solutions Inc has a 12 month low of $9.15 and a 12 month high of $26.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.42 and a quick ratio of 7.71. The stock has a market capitalization of $383.86 million, a P/E ratio of 148.43 and a beta of 1.37.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.02. BioLife Solutions had a net margin of 14.60% and a return on equity of 8.65%. The company had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.59 million. As a group, analysts anticipate that BioLife Solutions Inc will post 0.1 EPS for the current year.

A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its position in shares of BioLife Solutions by 36.1% in the 4th quarter. Bank of New York Mellon Corp now owns 64,930 shares of the medical equipment provider’s stock worth $781,000 after purchasing an additional 17,209 shares during the last quarter. Northern Trust Corp raised its stake in shares of BioLife Solutions by 19.2% in the 4th quarter. Northern Trust Corp now owns 49,729 shares of the medical equipment provider’s stock valued at $598,000 after purchasing an additional 8,003 shares during the period. Geode Capital Management LLC raised its stake in shares of BioLife Solutions by 34.1% in the 4th quarter. Geode Capital Management LLC now owns 83,588 shares of the medical equipment provider’s stock valued at $1,005,000 after purchasing an additional 21,267 shares during the period. Two Sigma Advisers LP raised its stake in shares of BioLife Solutions by 54.2% in the 4th quarter. Two Sigma Advisers LP now owns 25,900 shares of the medical equipment provider’s stock valued at $312,000 after purchasing an additional 9,100 shares during the period. Finally, Perkins Capital Management Inc. raised its stake in shares of BioLife Solutions by 19.7% in the 1st quarter. Perkins Capital Management Inc. now owns 60,750 shares of the medical equipment provider’s stock valued at $1,087,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 47.86% of the company’s stock.

Several research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. HC Wainwright assumed coverage on shares of BioLife Solutions in a research report on Monday, July 22nd. They set a “buy” rating and a $23.00 price target on the stock. Northland Securities reissued a “buy” rating and set a $18.00 price target on shares of BioLife Solutions in a research report on Tuesday, July 9th. Maxim Group set a $24.00 price target on shares of BioLife Solutions and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, ValuEngine cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $18.67.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: What Are Cryptocurrencies?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.